Cardiovascular – Renal Drugs : Antiplatelets and Thrombolytics
OAGRY1 “Agrylin capsule” 0.5 mg/cap
適應症：原發性血小板過多症。
Usual dose:
Thrombocythemia:
Adult: 0.5 mg qid or 1 mg bid for at least 1 wk, then dosage should be adjusted to the lowest effective dosage required to reduce and maintain platelet count < 600,00/mcL, and ideally to the normal range. The dosage should be increased by < 0.5 mg/day in any 1 wk. max. 10 mg/day or 2.5 mg single dose.
Dose adjustment:
Hepatic failure: initial, 0.5 mg/day for at least 1 wk, then max 0.5 mg/day increase in any 1 wk.
Contraindication: severe hepatic impairment.
Adverse effect:
Common: diarrhea, nausea, abdominal pain, dyspnea, edema, fever, headache, asthenia, dizziness, palpitations.
Serious: cerebrovascular accidents, CHF, MI, heart block, arrhythmia, pancreatitis, pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension, seizure.